Illumina
ILMN
$205.10
+0.00%
Illumina is a leading provider of tools and services for genetic analysis, primarily serving life science and clinical lab markets with sequencing instruments, consumables, and microarrays. As the dominant player in next-generation sequencing, Illumina commands over 90% of its revenue from sequencing-related products, giving it a formidable competitive moat in the genomics industry. The current investor narrative centers on the company's post-Grail spin-off recovery, accelerating revenue growth (4.8% YoY in Q1 2026), and expanding margins, though debates persist around competitive threats from newer sequencing technologies and the pace of clinical adoption.…
ILMN
Illumina
$205.10
Related headlines
Investment Opinion: Should I buy ILMN Today?
Rating: Hold. Illumina is a high-quality business with improving fundamentals, but the stock has already priced in much of the good news, trading above the average analyst target of $172.53. The consensus recommendation is Buy (mean 2.35), but the upside to the average target is negative (-11%), suggesting limited near-term appreciation.
Supporting Evidence: Revenue growth accelerated to 4.8% YoY in Q1 2026, gross margins expanded to 68.2%, and free cash flow of $989M TTM provides financial flexibility. The trailing P/E of 24.5x is reasonable relative to history, but the forward P/E of 32.7x implies expectations for earnings acceleration. The P/S of 4.8x is below the 5-year average of 8x, offering some valuation support. However, the stock has already rallied 80% over the past year, and the analyst high target of $220 offers only 13% upside.
Risks & Conditions: The Hold rating could upgrade to Buy if the stock pulls back to the $160-170 range (near the average target) or if revenue growth accelerates above 8% YoY. A downgrade to Sell would be warranted if competitive threats materially impact market share or if gross margins fall below 65%. Overall, Illumina is fairly valued relative to its growth prospects, but the risk/reward is balanced at current levels.
Sign up to view all
ILMN 12-Month Price Forecast
Illumina's fundamentals are improving, but the stock's 80% rally over the past year has largely priced in the recovery. The forward P/E of 32.7x leaves little room for error, and the analyst average target suggests limited upside. While the company's dominant market position and cash flow generation are attractive, the risk/reward is balanced at current levels. A neutral stance is warranted until either the stock pulls back to a more attractive entry point or growth accelerates convincingly above 6%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $172.53 and implied upside of -15.9% versus the current price.
Average Target
$172.53
0 analysts
Implied Upside
-15.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$95 - $220
Analyst target range
Illumina is covered by 19 analysts, with a consensus recommendation of 'Buy' (mean score 2.35 on a 1-5 scale where 1 is Strong Buy). The average price target is $172.53, which implies approximately -11% downside from the current price of $194.09. The distribution shows a bullish tilt, but the average target below the current price suggests that the stock has run ahead of analyst expectations. The target range is wide: low $95.00 and high $220.00, reflecting significant uncertainty. The high target of $220 implies 13% upside and likely assumes successful execution on new product launches and sustained market share gains. The low target of $95 suggests a scenario where competitive pressures or clinical setbacks materially impair growth. Recent ratings actions show a mix: JP Morgan upgraded from Neutral to Overweight in June 2026, while Barclays and Citigroup maintain Underweight/Sell ratings, indicating a divergence of opinion. The wide spread between low and high targets (125 points) signals high uncertainty, which is typical for a company undergoing a growth transition. Investors should weigh the bullish consensus against the fact that the stock has already surpassed the average target, suggesting that further upside may require upward revisions to estimates.
Bulls vs Bears: ILMN Investment Factors
Illumina presents a compelling bull case built on accelerating revenue growth, expanding margins, dominant market share, and robust free cash flow. The stock has rallied 80% over the past year, reflecting optimism around the post-Grail recovery. However, the current price has surpassed the average analyst target, and the forward P/E of 32.7x prices in significant growth acceleration. The central tension is whether Illumina can sustain its revenue growth trajectory (4.8% YoY) and defend its market share against emerging competitors. If growth accelerates further, the stock could re-rate higher; if it disappoints, the elevated multiple leaves room for downside. Overall, the bull case has stronger evidence from improving fundamentals, but valuation limits upside potential.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue grew 4.8% YoY to $1.091B, accelerating from 1.6% in Q4 2025, signaling a post-Grail recovery. Sequencing revenue, 91% of total, remains the core driver.
- Strong Profitability and Margins: Gross margin expanded to 68.2% in Q1 2026 from 65.8% a year ago, and operating margin held at 21.3%. Net income rose to $134M, with ROE of 31.2% reflecting efficient capital use.
- Dominant Market Position: Illumina commands over 90% of the next-generation sequencing market, providing a wide moat. High switching costs and an installed base of instruments create recurring consumable revenue.
- Robust Free Cash Flow: TTM free cash flow is $989M, yielding ~4.7% at current market cap. Q1 2026 FCF of $251M supports share repurchases ($242M in Q1) and strategic M&A.
Bearish
- Stock Above Average Target: At $194.09, ILMN trades 12.5% above the analyst average target of $172.53, implying limited near-term upside. The high target of $220 offers only 13% upside, capping potential.
- Elevated Forward P/E: Forward P/E of 32.7x is above the industry average (~22x) and the stock's own historical median, reflecting high growth expectations that may not materialize if revenue decelerates.
- Competitive Threats Emerging: New sequencing technologies from competitors like Element Biosciences and PacBio could erode Illumina's market share. Any loss of the >90% dominance would pressure margins and multiples.
- High Beta and Volatility: With a beta of 1.47, ILMN is 47% more volatile than the market. A broad market correction could amplify losses, as seen in the 25.66% max drawdown from recent highs.
ILMN Technical Analysis
Illumina is in a powerful sustained uptrend, with the stock up 80.3% over the past year and currently trading at 194.09, which is 97.5% of its 52-week high of 199.14. This positioning near the top of the range signals strong bullish momentum, though it also raises caution about potential overextension. The stock has rallied sharply from its 52-week low of 88.00, reflecting a complete reversal of the prior downtrend. Over the last three months, ILMN has surged 51.8%, and the one-month change of +10.9% shows accelerating short-term momentum that aligns with the longer-term uptrend. This consistent strength across time frames suggests broad-based buying pressure rather than a speculative spike. The relative strength versus the S&P 500 is impressive: ILMN has outperformed the market by 63.8% over one year and 48.3% over three months, indicating strong stock-specific catalysts. The 52-week high of 199.14 serves as immediate resistance; a breakout above this level would signal a continuation of the uptrend and likely attract further buying. Support lies at the 52-week low of 88.00, though the more relevant near-term support is around 175 (the June consolidation area). With a beta of 1.47, Illumina is 47% more volatile than the market, meaning larger swings in both directions—this amplifies gains in uptrends but also increases drawdown risk during market corrections.
Beta
—
—
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$88-$206
Price range past year
Annual Return
+99.7%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +11.5% | +0.2% |
| 3m | +51.1% | +3.7% |
| 6m | +41.6% | +8.0% |
| 1y | +99.7% | +18.2% |
| ytd | +52.7% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Illumina's revenue trajectory is improving, with Q1 2026 revenue of $1.091 billion growing 4.8% year-over-year, accelerating from the 1.6% growth in Q4 2025 and reversing the stagnation seen in prior quarters. Sequencing revenue of $995 million (91% of total) remains the primary growth driver, while microarray revenue of $96 million is stable but declining as a share. The multi-quarter trend shows a clear inflection: revenue grew from $1.041B in Q1 2025 to $1.091B in Q1 2026, with sequential improvement in each quarter. This acceleration supports the thesis that Illumina is regaining momentum after the Grail spin-off distraction. Profitability is solid and improving: net income in Q1 2026 was $134 million (EPS $0.88), up from $131 million in the year-ago quarter, and gross margin expanded to 68.2% from 65.8% a year earlier. Operating margin of 21.3% is healthy and consistent with recent quarters, indicating stable cost control. The company's net margin of 12.3% is respectable for a capital-intensive diagnostics firm, though below the 28.8% reported in Q4 2025 due to seasonality and higher R&D spending ($240M in Q1). Illumina's balance sheet is strong: debt-to-equity of 0.94 is manageable, and the current ratio of 2.08 indicates ample liquidity. Free cash flow generation is robust, with TTM FCF of $989 million and Q1 2026 FCF of $251 million, giving a FCF yield of approximately 4.7% at the current market cap. The company is using cash for share repurchases ($242M in Q1 2026) and acquisitions ($415M in Q1), signaling confidence in its growth prospects. ROE of 31.2% is exceptional, reflecting efficient capital use and strong profitability.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+4.8%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$989000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Since Illumina is profitable (net income of $134M in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E stands at 24.5x, while the forward P/E is 32.7x, implying the market expects earnings growth to accelerate. The gap between trailing and forward multiples suggests analysts anticipate higher earnings in the coming year, which is consistent with the revenue acceleration story. Compared to the industry average P/E (not provided, but typically ~22x for medical diagnostics), Illumina's trailing P/E of 24.5x represents a modest 11% premium. However, the forward P/E of 32.7x is more stretched, reflecting optimism about future growth. The PEG ratio of -0.14 is negative due to negative earnings growth in the trailing period (distorted by Grail-related charges), making it less useful. Historically, Illumina's trailing P/E has ranged from about 15x to over 100x over the past five years. The current 24.5x is near the lower end of its historical range, suggesting the stock is not excessively valued by historical standards. However, the forward P/E of 32.7x is above the midpoint, indicating that the market is pricing in a meaningful growth recovery. The P/S ratio of 4.8x is below the 5-year average of ~8x, further supporting the view that valuation is reasonable relative to sales.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Illumina's debt-to-equity of 0.94 is manageable but not negligible, and the company carries $26M in quarterly interest expense. While free cash flow is strong, the heavy reliance on sequencing consumables (91% of revenue) creates concentration risk—any disruption in instrument adoption or competitive displacement could directly impact top-line growth. The net margin of 12.3% in Q1 2026, though improved, is below the 28.8% in Q4 2025, indicating quarterly volatility from R&D spending ($240M) and other costs.
Market & Competitive Risks: The stock's forward P/E of 32.7x is a premium to the medical diagnostics industry average of ~22x, leaving it vulnerable to multiple compression if growth disappoints. With a beta of 1.47, ILMN is highly correlated to market swings, and a rotation out of growth stocks could trigger selling. Competitive threats from newer sequencing platforms (e.g., Element Biosciences) could erode Illumina's >90% market share, a key pillar of its investment thesis. Regulatory risks include FDA oversight of clinical tests and potential changes to reimbursement for genomic sequencing.
Worst-Case Scenario: A combination of competitive market share loss, revenue growth deceleration below 2%, and a broad market downturn could drive the stock to its 52-week low of $88.00, representing a 54.6% decline from the current price of $194.09. This scenario would likely involve multiple quarters of missed earnings, analyst downgrades, and a re-rating to a P/E below 15x. Investors could lose over half their investment in this adverse case.
FAQ
The primary risk is competitive disruption: new sequencing technologies could erode Illumina's >90% market share, directly impacting revenue growth. Second, the stock's forward P/E of 32.7x makes it vulnerable to multiple compression if growth decelerates below 4%. Third, with a beta of 1.47, ILMN is highly sensitive to market downturns, as evidenced by its 25.66% max drawdown. Finally, clinical adoption of NGS may be slower than expected, dampening the long-term growth narrative. The most severe risk is a 54.6% decline to the 52-week low of $88.00 if multiple risks materialize simultaneously.
The 12-month outlook is balanced: the base case (50% probability) sees the stock trading between $160 and $195, with revenue growing 4-5% YoY. The bull case (25% probability) targets $195-$220, driven by accelerating growth above 6% and margin expansion. The bear case (25% probability) sees the stock falling to $95-$140 if competitive pressures or macro headwinds slow growth below 2%. The analyst consensus is Buy, but the average target of $172.53 implies -11% downside from the current price, suggesting the stock has already priced in much of the optimism.
Illumina's trailing P/E of 24.5x is near the low end of its 5-year historical range (15x-100x) and below the sector average of ~22x, suggesting it is not overvalued on a trailing basis. However, the forward P/E of 32.7x is above both the sector average and the stock's own historical median, indicating the market expects earnings growth to accelerate. The P/S ratio of 4.8x is well below the 5-year average of 8x, supporting a fair valuation relative to sales. Overall, Illumina is fairly valued given its growth prospects, but the forward multiple leaves little room for disappointment.
Illumina is a high-quality business with improving fundamentals, but at $194.09, the stock trades above the average analyst target of $172.53, implying limited near-term upside. The trailing P/E of 24.5x is reasonable, but the forward P/E of 32.7x prices in significant growth acceleration. For long-term investors willing to hold through volatility, Illumina's dominant market position and strong free cash flow ($989M TTM) make it a solid core holding. However, for those seeking near-term gains, the risk/reward is balanced, and a pullback to the $160-170 range would offer a better entry point.
Illumina is better suited for long-term investment given its dominant market position, recurring revenue model, and exposure to secular growth in genomics. The stock's high beta (1.47) and recent 80% rally make it less attractive for short-term trading, as it is prone to sharp pullbacks. A minimum holding period of 3-5 years is recommended to allow the clinical adoption story to unfold and to smooth out volatility. The company pays no dividend, so total return depends on capital appreciation. For short-term traders, the stock's momentum could offer opportunities, but the risk of a correction is elevated near its 52-week high.